New hope for mesothelioma patients who Can't have surgery?
NCT ID NCT05449366
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with a rare cancer called malignant peritoneal mesothelioma. The 7 participants could not have standard surgery. The main goal was to find the safest dose and see if the treatment is feasible. Researchers also checked for side effects and how the drug behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Paclitaxel (chemotherapy drug given directly into the abdomen)
- What this could lead to
- If successful, this could provide a new treatment option for patients with peritoneal mesothelioma who cannot have surgery, potentially controlling the disease and improving survival.
- What could go wrong
- This is a very small, early-phase study (only 7 participants) focused on finding the right dose and checking safety. It is not designed to prove the treatment works, and side effects from chemotherapy are expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERITONEAL MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erasmus Medical Center
Rotterdam, South Holland, 3000 CA, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.